Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation

  • STATUS
    Recruiting
  • End date
    Jan 1, 2032
  • participants needed
    314
  • sponsor
    Heidelberg University
Updated on 19 February 2024

Summary

Adenoid cystic tumors are rare tumors of the head and neck region. Despite their slow growth, re-irradiation is often necessary due to the high metastatic risk. Patients are usually irradiated with photons or, as here at the Heidelberg University Hospital, with a combination of carbon ions and photons. So far, there is no data from Europe available for the sole irradiation with carbon ions. The present ACCO (Adenoid Cystic Carcinoma and Carbon ion Only irradiation) study, a prospective, open-label, phase II, single-arm, investigator-initiated study, will therefore investigate the sole radiotherapy of carbon ions in this tumor entity. Irradiation is applied - significantly shorter than the combination therapy - in about 4 weeks (22 fractions); patients are followed up for further 5 years after the start of therapy. Carbon ions alone are expected to increase local tumor control rates from 60% to 70% after 5 years (primary objective criterion of this study). In order to reject the null hypothesis with a power of 80% and a significance level of 5%, 175 patients are included (including a drop-out rate of 15%). Secondary objective criteria are progression-free survival, overall survival, acute and late toxicity, and quality of life.

Details
Condition Adenocarcinoma, Adenocarcinoma, Adenoid Cystic Carcinoma
Age 18years - 80years
Treatment Carbon ion irradiation, Bimodal irradiation
Clinical Study IdentifierNCT04214366
SponsorHeidelberg University
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically confirmed adenoid cystic carcinoma in the head and neck area
Indication for irradiation
non-operable or
R1/R2 resected or
perineural sheat invasion (Pn+) or
pT3/pT4
Informed consent
KI > 60% or ECOG 0/1 (minimum: self-sufficiency, normal activity or work not possible)
Age 18-80 years

Exclusion Criteria

rejection of the study by the patient
Patient is not able to consent
Stage IV (distant metastases), except lung metastases < 1cm
lymph node involvement (clinical or pathological)
Previous radiotherapy in the head and neck area
Active medical implants for which there is no ion radiation authorization at the time of treatment (e.g., cardiac pacemaker, defibrillator, ...)
Contraindication to MR imaging
Simultaneous participation in another clinical study that could influence the outcome of this study or the other study
Pregnancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.